0.8814
price down icon3.14%   -0.0286
 
loading
Precedente Chiudi:
$0.91
Aprire:
$0.9212
Volume 24 ore:
21,200
Relative Volume:
0.17
Capitalizzazione di mercato:
$31.35M
Reddito:
-
Utile/perdita netta:
$-9.16M
Rapporto P/E:
-1.5463
EPS:
-0.57
Flusso di cassa netto:
$-8.75M
1 W Prestazione:
-11.86%
1M Prestazione:
-6.30%
6M Prestazione:
-13.59%
1 anno Prestazione:
-26.55%
Intervallo 1D:
Value
$0.8602
$0.97
Intervallo di 1 settimana:
Value
$0.8001
$1.03
Portata 52W:
Value
$0.7736
$1.6899

Renovorx Inc Stock (RNXT) Company Profile

Name
Nome
Renovorx Inc
Name
Telefono
408-800-2649
Name
Indirizzo
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
2024-08-15
Name
Ultimi documenti SEC
Name
RNXT's Discussions on Twitter

Confronta RNXT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RNXT
Renovorx Inc
0.8814 31.35M 0 -9.16M -8.75M -0.57
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Renovorx Inc Borsa (RNXT) Ultime notizie

pulisher
Apr 06, 2025

HC Wainwright Reaffirms “Buy” Rating for RenovoRx (NASDAQ:RNXT) - Defense World

Apr 06, 2025
pulisher
Apr 04, 2025

H.C. Wainwright maintains Buy rating on RenovoRx stock By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

H.C. Wainwright maintains Buy rating on RenovoRx stock - Investing.com Australia

Apr 04, 2025
pulisher
Apr 04, 2025

Revolutionary Pancreatic Cancer Treatment Update: RenovoRx CEO Presents Latest Clinical Trial Results - Stock Titan

Apr 04, 2025
pulisher
Apr 01, 2025

RenovoRx Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

RenovoRx projects growth with new orders and clinical trial - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

RenovoRx Hits Major Milestone: First Revenue from Cancer Device as Phase 3 Trial Nears Key Analysis - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

RenovoRx, Inc. SEC 10-K Report - TradingView

Apr 01, 2025
pulisher
Mar 31, 2025

RenovoRx Delays Yearly Report Filing - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - Business Wire

Mar 31, 2025
pulisher
Mar 31, 2025

RenovoRx (RNXT) to Release Earnings on Monday - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

HC Wainwright Estimates RenovoRx FY2024 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

RenovoRx Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting - BioSpace

Mar 28, 2025
pulisher
Mar 28, 2025

Breakthrough: RenovoRx's Pancreatic Cancer Treatment Shows Promise with Reduced Systemic Exposure - Stock Titan

Mar 28, 2025
pulisher
Mar 28, 2025

RenovoRx (NASDAQ:RNXT) Coverage Initiated by Analysts at HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

HC Wainwright & Co. Initiates Coverage of RenovoRx (RNXT) with Buy Recommendation - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

HC Wainwright Initiates Coverage on RenovoRx With Buy Rating, $3 Price Target - MarketScreener

Mar 27, 2025
pulisher
Mar 26, 2025

RenovoRx honored for cancer treatment research By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting - BioSpace

Mar 26, 2025
pulisher
Mar 26, 2025

RenovoRx honored for cancer treatment research - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

RenovoRx (NASDAQ:RNXT) Stock Price Up 11.5% – Should You Buy? - Defense World

Mar 25, 2025
pulisher
Mar 20, 2025

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET - Business Wire

Mar 20, 2025
pulisher
Mar 20, 2025

RenovoRx Reveals Commercial Milestones and Phase 3 Trial Updates for Revolutionary Pancreatic Cancer Treatment - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025 - Business Wire

Mar 19, 2025
pulisher
Mar 15, 2025

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026 - Business Wire

Mar 15, 2025
pulisher
Feb 26, 2025

RenovoRx launches public stock offering - MSN

Feb 26, 2025
pulisher
Feb 26, 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders - BioSpace

Feb 26, 2025
pulisher
Feb 26, 2025

with Several New Purchase Orders, Including Customer Reorders - Business Wire

Feb 26, 2025
pulisher
Feb 26, 2025

Can RenovoRx's Premium-Priced Cancer Device Deliver on its $400M Market Potential? - Stock Titan

Feb 26, 2025
pulisher
Feb 14, 2025

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery - BioSpace

Feb 14, 2025
pulisher
Feb 12, 2025

RenovoRx Announces $10.9 Million Public Offering of Common Stock - Defense World

Feb 12, 2025
pulisher
Feb 11, 2025

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire

Feb 11, 2025
pulisher
Feb 11, 2025

RenovoRx (RNXT) Lands Major $12.1M Healthcare Investor Backing for Cancer Treatment Launch - Stock Titan

Feb 11, 2025
pulisher
Feb 10, 2025

A better buy-in window may exist right now for RenovoRx Inc (RNXT) - SETE News

Feb 10, 2025
pulisher
Feb 10, 2025

Closing Figures: RenovoRx Inc (RNXT)’s Negative Finish at 1.16, Down -20.55 - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Trading Day Review: Unicycive Therapeutics Inc (UNCY) Loses Momentum, Closing at 0.57 - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

RenovoRx Inc (RNXT) Stock: A Year of Decreases and Increases - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

RenovoRx Inc (RNXT) Stock: Tracking the Weekly Performance - The News Heater

Feb 10, 2025
pulisher
Feb 08, 2025

RenovoRx 11.52M share Spot Secondary priced at $1.05 - MSN

Feb 08, 2025
pulisher
Feb 08, 2025

RenovoRx (NASDAQ:RNXT) Stock Price Down 20.5% – Should You Sell? - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

RenovoRx announces proposed public offering - MSN

Feb 07, 2025
pulisher
Feb 07, 2025

RenovoRx Prices $12.1 Million Public Offering; Shares Decline Po - GuruFocus.com

Feb 07, 2025
pulisher
Feb 07, 2025

RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement - Yahoo Finance

Feb 07, 2025
pulisher
Feb 07, 2025

RenovoRx prices public offering to raise $12.1M - MSN

Feb 07, 2025
pulisher
Feb 07, 2025

RenovoRx launches public stock offering By Investing.com - Investing.com Nigeria

Feb 07, 2025
pulisher
Feb 06, 2025

RenovoRx Announces Pricing Of Public Offering Of About 11.52 Million Shares At $1.05/shr - Nasdaq

Feb 06, 2025
pulisher
Feb 06, 2025

RenovoRx Secures Critical $12.1M Funding: Phase III Cancer Study Gets Green Light - StockTitan

Feb 06, 2025
pulisher
Feb 06, 2025

Renovorx Announces Pricing Of $12.1 Million Underwritten Public Offering Of Common Stock - Marketscreener.com

Feb 06, 2025
pulisher
Feb 06, 2025

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire

Feb 06, 2025

Renovorx Inc Azioni (RNXT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):